Company profile
JOHNSON & JOHNSON
NYSE:JNJBiotechnology: Pharmaceutical Preparations
Drug pipeline (157)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DARATUMUMAB | approved | $4.2BQ2 2026 | 37 | approved |
| GUSELKUMAB | approved | $2.0BQ2 2026 | 54 | approved |
| Paliperidone | approved | $1.0BQ2 2026 | 13 | approved |
| Paliperidone Palmitate | approved | $1.0BQ2 2026 | 29 | approved |
| Apalutamide | approved | $995.0MQ2 2026 | 17 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2299)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01157351 | phase4 | completed | 2010-05-01 | 2013-12-01 | Janssen Scientific Affairs, LLC | 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated |
| NCT00752427 | phase3 | completed | 2004-06-01 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia |
| NCT00946985 | phase4 | terminated | 2009-06-01 | 2010-03-01 | Ortho-McNeil Janssen Scientific Affairs, LLC | 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years |
| NCT01349465 | phase3 | completed | 2011-07-04 | 2016-01-05 | Janssen R&D Ireland | 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection |
| NCT03039192 | phase3 | completed | 2017-06-09 | 2018-12-18 | Janssen Research & Development, LLC | 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide |
FDA applications (135)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 060618 | ANDA | JOHNSON AND JOHNSON CONSUMER PRODUCTS INC | ||||
Loading… | ||||||
| ANDA 070081 | ANDA | JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIV | ||||
Loading… | ||||||
| ANDA 070475 | ANDA | MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC | ||||
Loading… | ||||||
| ANDA 070476 | ANDA | MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC | ||||
Loading… | ||||||
| ANDA 070767 | ANDA | JANSSEN PHARMACEUTICA PRODUCTS LP | ||||
Loading… | ||||||